In Vitro Efficacy Testing Services for Hypoglycemia

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Hypoglycemia. Our service offers comprehensive assessment of drug candidates for their effects on insulin secretion, glucose metabolism, and key hormonal pathways involved in blood glucose regulation. We focus on targets such as insulin receptors, glucagon-like peptide-1 (GLP-1) receptors, somatostatin receptors, KATP channels, and associated signaling molecules. Our assays enable evaluation of pathological processes relevant to Hypoglycemia, including impaired glucose uptake, dysregulated insulin release, and altered counter-regulatory hormone responses.

Our portfolio encompasses a wide range of in vitro assays, including binding, functional, cell-based, biochemical, and biophysical methods to evaluate drug activity and mechanism of action. These assays allow for precise measurement of interactions with key hypoglycemia-related targets, assessment of functional outcomes, and characterization of drug-receptor binding kinetics. The diversity of platforms ensures comprehensive profiling of candidate compounds.

Arrestin protease recruitment assay: Measures recruitment of arrestin to receptors, providing insights into receptor activation and downstream signaling pathways relevant to glucose regulation.

Arrestin protease recruitment assay (with bovine serum albumin (0.1%)): Assesses arrestin recruitment in the presence of BSA to mimic physiological protein binding conditions.

Arrestin protease recruitment assay (with casein (0.1%)): Evaluates arrestin recruitment with casein to assess potential effects of protein interference on assay outcomes.

Bioluminescence resonance energy transfer (BRET) assay: Monitors protein-protein interactions in live cells, useful for studying receptor signaling and G protein-coupled receptor (GPCR) function.

Cell-based assay: Evaluates cellular responses such as insulin secretion, glucose uptake, or receptor activation in relevant cell lines.

Chemiluminescent assay: Detects target analytes or activities through light emission, enabling sensitive quantification of hormones or metabolites.

Competitive binding assay: Determines the affinity of compounds for specific receptors by measuring their ability to compete with labeled ligands.

Displacement of [125I]-MK-678: Quantifies binding to somatostatin receptors by measuring displacement of a radiolabeled ligand.

Displacement of [125I]-[Leu8,D-Trp22,Tyr25]-somatostatin-28: Assesses ligand binding to somatostatin receptor subtypes implicated in glucose regulation.

Displacement of [125I]-[Tyr11]-somatostatin: Evaluates compound interaction with somatostatin receptors using radiolabeled ligand displacement.

Displacement of [125I]-[Tyr11]-somatostatin-14: Measures binding affinity for somatostatin-14 sensitive pathways.

Displacement of [125I]-[Tyr3]-octreotide: Assesses binding to somatostatin receptor subtypes via displacement of a peptide analog.

Displacement of [125I]-exendin: Evaluates compound affinity for GLP-1 receptors, important in incretin-based hypoglycemia therapies.

Displacement of [125I]-glucagon: Quantifies binding to glucagon receptors, which play a role in glucose counter-regulation.

Displacement of [125I]-glucagon-like polypeptide 1: Assesses binding affinity to GLP-1 receptors using labeled ligand.

Displacement of [3H]-glibenclamide: Measures interaction with KATP channels, critical for insulin secretion modulation.

ELISA assay: Enables sensitive quantification of hormones such as insulin, glucagon, or GLP-1 in biological samples.

Enzyme immunoassay (EIA): Detects and quantifies specific proteins or peptides using antigen-antibody interactions.

Flow cytometry assay: Analyzes cellular markers and functional responses at the single-cell level, useful for monitoring cell populations.

Fluorescence resonance energy transfer (FRET) assay: Detects molecular interactions and conformational changes through energy transfer between fluorophores.

Fluorescent assay: Measures target activity or presence using fluorescent probes, applicable to glucose transporter activity and more.

Fluorescent-activated cell sorting (FACS) assay: Sorts and quantifies cells based on fluorescent labeling, enabling analysis of specific cell subpopulations.

Gene reporter assay: Monitors activation of gene expression pathways relevant to glucose metabolism and insulin signaling.

Hoechst33342 uptake assay: Assesses cell viability or membrane integrity using a fluorescent dye.

Homogeneous Time Resolved Fluorescence (HTRF) assay: Provides sensitive, high-throughput quantification of biomolecules or protein interactions.

Homogeneous Time Resolved Fluorescence (HTRF) assay (with 0.1 % casein): Optimizes assay conditions to minimize non-specific binding.

Homogeneous Time Resolved Fluorescence (HTRF) assay (with fetal bovine serum/bovine serum albumin): Mimics physiological protein concentrations for enhanced assay relevance.

Immunoradiometric assay: Quantifies hormones or proteins using radiolabeled antibodies, offering high sensitivity.

Isothermal titration calorimetric assay: Measures binding thermodynamics and affinities of drug-target interactions.

Luciferine/luciferase assay: Detects ATP or other metabolites via luminescence, applicable to cell viability or signaling studies.

Maltose as substrate: Used in enzymatic assays to monitor glucose metabolism-related enzyme activity.

Patch-clamp assay: Measures ionic currents through membrane channels, critical for studying KATP channel activity.

RNA assay: Quantifies gene expression changes induced by test compounds in pathways relevant to hypoglycemia.

Radioactivity assay: Detects radiolabeled compounds or metabolites, enabling highly sensitive quantification.

Saturation binding assay: Determines receptor density and binding characteristics of test compounds.

Scintillation proximity assay (SPA): Measures binding events without separation steps, improving assay speed and throughput.

Short-circuit current assay: Monitors ion transport across epithelial layers, relevant for glucose absorption studies.

Sucrose as substrate: Used in assays evaluating enzyme activities in carbohydrate metabolism.

Surface plasmon resonance assay: Provides real-time measurement of biomolecular interactions and binding kinetics.

Surface plasmon resonance assay (At 25 degree Celsius): Measures binding kinetics at ambient temperature, useful for stability assessment.

Surface plasmon resonance assay (At 37 degree Celsius): Assesses binding interactions at physiological temperature for increased relevance.

Thallium flux assay: Evaluates ion channel activity, especially potassium channels involved in insulin secretion.

Whole-cell patch-clamp assay: Records currents from entire cells to assess ion channel function and drug effects.

With bovine serum albumin (0.1%): Indicates inclusion of BSA in assay buffer to simulate physiological protein binding.

With casein (0.1%): Uses casein in assay buffer to reduce non-specific binding and mimic physiological conditions.

beta-Galactosidase assay: Monitors gene expression via enzymatic activity, often as a reporter for pathway activation.

cAMP accumulation assay: Measures intracellular cAMP levels, a key second messenger in GPCR-mediated glucose regulation.

We measure a comprehensive range of pharmacological parameters, including potency, efficacy, affinity, and functional activity, to provide detailed insights into candidate drug profiles. These parameters help determine the strength, effectiveness, and mechanism of action of compounds targeting hypoglycemia-related pathways. Accurate parameter measurement is essential for lead optimization, dose selection, and risk assessment in drug development.

EC-50: The concentration of a compound that produces 50% of its maximal effect, indicating compound potency.

IC-50: The concentration required to inhibit a biological process by 50%, used to assess inhibitor strength.

Kd: The equilibrium dissociation constant, reflecting the binding affinity between ligand and target.

Ki: The inhibition constant, quantifying the binding affinity of an inhibitor for its target.

MEC: Minimum Effective Concentration, the lowest concentration at which a compound elicits a desired effect.

MIC: Minimum Inhibitory Concentration, the lowest concentration that prevents detectable biological activity (typically microbial growth, but relevant for certain pathway inhibitions).

pEC-50: The negative logarithm of EC-50, used to present potency on a logarithmic scale for easier comparison.

pIC-50: The negative logarithm of IC-50, providing a standardized measure of inhibitory potency.

pKb: The negative logarithm of the equilibrium dissociation constant for a base, indicating binding affinity.

pKi: The negative logarithm of the inhibition constant, enabling comparative analysis of inhibitor binding strengths.

Recommended In Vitro Efficacy Tests

Alpha Glucosidase

Alpha Glucosidase plays a key role in carbohydrate digestion, impacting blood glucose levels and hypoglycemia risk. Alpha Glucosidase testing is crucial in hypoglycemia drug development to evaluate inhibitor efficacy. Using maltose or sucrose as substrates, the assay quantifies enzyme inhibition, with IC50 values indicating compound potency. This enables precise screening of drug candidates targeting postprandial glucose control.

Estrogen Related Receptor Gamma

Estrogen Related Receptor Gamma (ERRγ) regulates glucose metabolism and is implicated in hypoglycemia. Our testing service evaluates ERRγ’s role in hypoglycemia drug development using RNA assays, isothermal titration calorimetry, and luciferin/luciferase reporter assays. These methods measure ERRγ activity and binding, providing critical parameters such as dissociation constant (Kd) and half-maximal inhibitory concentration (IC-50), essential for assessing drug efficacy and potency.

G Protein-Coupled Receptor 119

G Protein-Coupled Receptor 119 (GPR119) is involved in glucose homeostasis and is a promising target for hypoglycemia drug development. Our GPR119 testing service utilizes short-circuit current assays to assess compound efficacy, measuring key parameters such as EC-50 to determine potency. This testing is essential for identifying effective drug candidates that modulate GPR119 activity, supporting the development of novel therapies for hypoglycemia.

Glucagon Like Peptide 1 Receptor

The Glucagon Like Peptide 1 Receptor (GLP-1R) regulates insulin secretion, playing a critical role in hypoglycemia management and drug development. Accurate GLP-1R testing is essential for evaluating drug efficacy and receptor interaction. We utilize advanced methods—EIA, HTRF, FRET, radioactivity, surface plasmon resonance, cAMP accumulation, and gene reporter assays—to measure key parameters such as pKb, Ki, EC-50, IC-50, Kd, and more, ensuring robust pharmacological profiling.

Glucagon Receptor

The Glucagon Receptor plays a pivotal role in counteracting hypoglycemia by stimulating hepatic glucose release. Accurate testing of this receptor is essential for hypoglycemia drug development to ensure efficacy and safety. Our comprehensive service utilizes advanced assays—including HTRF, FRET, SPR (at 25°C/37°C), immunoradiometric, gene reporter, ELISA, and competitive binding—to evaluate key parameters such as Ki, EC-50, IC-50, Kd, and pEC-50, using various protein supplements for optimal assay performance.

Insulin Receptor

The Insulin Receptor testing service evaluates drug interactions critical for hypoglycemia management, as receptor activation regulates blood glucose levels. This service employs surface plasmon resonance, FACS, flow cytometry, and chemiluminescent assays to assess receptor binding and signaling. Key parameters analyzed include EC-50 (potency), Kd (binding affinity), and IC-50 (inhibitory concentration), providing essential data for optimizing hypoglycemia drug candidates.

Interleukin 1 Beta

Interleukin 1 Beta (IL-1β) is a key pro-inflammatory cytokine implicated in hypoglycemia-related neuroinflammation and metabolic dysregulation. Testing IL-1β is crucial for evaluating drug efficacy and safety in hypoglycemia drug development. We offer Surface Plasmon Resonance, Chemiluminescent, ELISA, cell-based, and RNA assays to quantify IL-1β and analyze drug interactions. Main parameters measured include MEC (Minimum Effective Concentration), Kd (binding affinity), and IC-50 (inhibitory potency).

Potassium Inwardly Rectifying Channel Subfamily J Member 11

The Potassium Inwardly Rectifying Channel Subfamily J Member 11 (KIR6.2) regulates insulin secretion and plays a crucial role in hypoglycemia. Testing its function is vital for developing drugs targeting hypoglycemic disorders. Our service utilizes fluorescent, thallium flux, and patch-clamp assays, [3H]-glibenclamide displacement, and whole-cell patch-clamp techniques. Key parameters measured include EC-50, pEC-50, and IC-50, enabling precise evaluation of compound efficacy and potency.

Pyroglutamylated Rfamide Peptide Receptor

Our Pyroglutamylated Rfamide Peptide Receptor testing service supports hypoglycemia drug development by evaluating receptor activity, crucial for glucose homeostasis regulation. This service uses a sensitive fluorescent assay to quantify receptor-ligand interactions, providing accurate EC-50 measurements. Assessing EC-50 values enables precise determination of compound potency and efficacy, essential for identifying promising therapeutics targeting hypoglycemia via this receptor pathway.

Solute Carrier Family 5 Member 1

The Solute Carrier Family 5 Member 1 (SGLT1) mediates intestinal and renal glucose absorption, impacting hypoglycemia risk. Testing SGLT1 is vital for hypoglycemia drug development to assess glucose uptake modulation. Key methods include in vitro transporter assays, uptake inhibition studies, and cell-based models. Main parameters measured are glucose transport rates, inhibitor potency (IC50), and selectivity, enabling effective screening and optimization of candidate drugs.

Somatostatin Receptor 1

Somatostatin Receptor 1 (SSTR1) modulates insulin secretion and glucose homeostasis, making it a key target in hypoglycemia drug development. Testing SSTR1 involves displacement assays with [125I]-[Tyr11]-somatostatin/-14, radioactivity, chemiluminescent assays, cAMP accumulation, and arrestin protease recruitment assays. These methods assess ligand binding and functional activity, generating critical parameters such as Ki, pKi, pEC-50, and IC-50 for drug candidate evaluation.

Somatostatin Receptor 2

Somatostatin Receptor 2 (SSTR2) regulates insulin secretion, playing a crucial role in hypoglycemia. Testing SSTR2 is essential for developing targeted hypoglycemia therapies. Our service employs advanced methods—radioligand displacement ([125I]-labeled analogs), fluorescent, chemiluminescent, radioactivity, ELISA, cAMP accumulation, and arrestin recruitment assays—to assess compound efficacy and receptor interaction. Key parameters measured include Ki, pKi, EC-50, pEC-50, IC-50, and pIC-50, ensuring robust drug candidate evaluation.

Somatostatin Receptor 3

Our Somatostatin Receptor 3 (SSTR3) testing service supports hypoglycemia drug development by evaluating compounds that target SSTR3, a key modulator of insulin secretion. This testing is crucial for identifying candidates that can regulate glucose levels. We employ advanced methods—including fluorescent, chemiluminescent, radioactivity, ELISA, cAMP accumulation, and arrestin recruitment assays—measuring parameters such as Ki, pKi, EC-50, pEC-50, and IC-50 to ensure precise pharmacological profiling.

Somatostatin Receptor 5

Our Somatostatin Receptor 5 (SSTR5) testing service supports hypoglycemia drug development by evaluating compounds that modulate SSTR5, a key regulator of insulin secretion. Accurate SSTR5 profiling is essential for identifying therapeutics that prevent hypoglycemic episodes. We employ advanced assays—fluorescent, chemiluminescent, ELISA, radioactive displacement ([125I]-[Tyr11]-somatostatin-14), cAMP accumulation, and arrestin recruitment. Key parameters measured include Ki, EC-50, IC-50, pIC-50, and pKi, enabling robust pharmacological characterization.

Trace Amine Associated Receptor 1

Trace Amine Associated Receptor 1 (TAAR1) modulates insulin secretion and glucose homeostasis, making it a promising target in hypoglycemia drug development. TAAR1 testing is crucial to identify compounds that regulate blood glucose levels. Our service utilizes Bioluminescence Resonance Energy Transfer (BRET) assays to assess ligand-receptor interactions, with EC-50 values determining compound potency. This enables efficient screening and optimization of candidate therapeutics for hypoglycemia management.